enVVeno Medical Corp 10-Q

Item 5. Other Information Reference is made to our Current Report on Form 8-K filed on May 20, 2025 reporting the appointment of Jennifer Bright as Chief Financial Officer of the Company. Attached hereto as Exhibit 10.1 and Exhibit 99.1 are the employment agreement, dated May 19, 2025, between the Company and Ms. Bright and the Officer Indemnity Agreement entered into by and between the Company and Ms. Bright. Trading Arrangements On June 12, 2025 , Dr. Francis Duhay , a director of the Company, adopted a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act) (with the first trade under the new plan not to be made prior to September 15, 2025). The trading plan will be effective until September 30, 2026 and provides for the sale of 20,000 shares of common stock. 15 Item 6. Exhibits The following is a complete list of exhibits filed as part of this Form 10-Q. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K. Exhibit Description 10.1 Employment Agreement, dated as of May 19, 2025, by and between enVVeno Medical Corporation and Jennifer Bright* 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act* 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Sarbanes-Oxley Act* 32 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act** 99.1 Officer Indemnity Agreement, dated July 26, 2025, by and between enVVeno Medical Corporation and Jennifer Bright* 101.INS Inline XBRL Instance Document* 101.SCH Inline XBRL Taxonomy Extension Schema Document* 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document* 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document* 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document* 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith. ** These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. 16 SIGNATURES Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: July 31, 2025 ENVVENO MEDICAL CORPORATION By: /s/ Robert Berman Robert Berman Chief Executive Officer (Principal Executive Officer) By: /s/ Jennifer Bright Jennifer Bright Chief Financial Officer (Principal Financial and Accounting Officer) 17